TY - JOUR
T1 - Diagnostic utility of presepsin in infections after liver transplantation
T2 - A preliminary study
AU - Yokose, Takahiro
AU - Takeuchi, Masashi
AU - Obara, Hideaki
AU - Shinoda, Masahiro
AU - Kawakubo, Hirofumi
AU - Kitago, Minoru
AU - Yagi, Hiroshi
AU - Abe, Yuta
AU - Yamada, Yohei
AU - Matsubara, Kentaro
AU - Oshima, Go
AU - Hori, Shutaro
AU - Fujimura, Takumi
AU - Takemura, Ryo
AU - Ishii, Ryota
AU - Kuroda, Tatsuo
AU - Kitagawa, Yuko
N1 - Funding Information:
We would like to thank Kaili Chen, a member of the Department of Surgery at Keio University School of Medicine, for assistance with collecting the samples. The work was supported through donations from the Keio University and LSI Medience Corporation. LSI Medience Corporation was not involved in the planning of the protocol nor the conduct of the trial or the data analysis.
Funding Information:
* Takahiro Yokose and Masashi Takeuchi contributed equally to this work Hideaki Obara, e-mail: obara.z3@keio.jp Donations from the Keio University School of Medicine and LSI Medience Corporation. LSI Medience Corporation was not involved in the planning of the protocol, nor in the conduct of the trial or the data analysis Masashi Takeuchi is a member of the speaker’s bureau of Otsuka Pharmaceutical Factory Inc., outside the submitted work. Hideaki Obara has received grants from Taiho Pharmaceutical Co., Ltd., Japan Blood Products Organization, and Mitsubishi Tanabe Pharma Co., Ltd., outside the submitted work. Masahiro Shinoda has received grants from Taiho Pharmaceutical Co., Ltd., Shionogi Co., Ltd., Eisai Co., Ltd. Novartis Pharma K.K., Asahi KASEI Co., Ltd., and Daiichi Sankyo Co., Ltd., outside the submitted work. Ryota Ishii has received personal fees from Kowa Company, Ltd., outside the submitted work. Yuko Kitagawa has received grants from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Daiichi Sankyo Co., Ltd., Merck Serono Co., Ltd., Asahi KASEI Co., Ltd., EA Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc., Shionogi Co., Ltd., Kaken Pharmaceutical Co., LTD., Kowa Pharmaceutical Co., Ltd., Astellas Pharma Inc., Medicon Inc., Dainippon Sumitomo Pharma Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Kyouwa Hakkou Kirin Co., Ltd., Pfizer Japan Inc., Ono Pharmaceutical CO., LTD., Nihon Pharmaceutical CO., LTD., Japan Blood Products Organization, Medtronic Japan Co., Ltd., Sanofi K.K., Eisai Co., Ltd., Tsumura Co., KCI Licensing, Inc., Abbott Japan CO., LTD., and Fujifilm Toyama Chemical Co., Ltd., outside the submitted work. All other authors have no conflict of interest
Funding Information:
Donations from the Keio University School of Medicine and LSI Medience Corporation. LSI Medience Corporation was not involved in the planning of the protocol, nor in the conduct of the trial or the data analysis.
Publisher Copyright:
© Ann Transplant,.
PY - 2021
Y1 - 2021
N2 - Background: Infectious complications after solid organ transplantation can be fatal, and early diagnosis and intervention are important. To the best of our knowledge, no study has examined the diagnostic utility of presepsin, a known accurate biomarker, for infectious complications after liver transplantation. This study aimed to evaluate the utility of presepsin for detecting infection and perioperative kinetics of presepsin after liver transplantation. Material/Methods: This single-institutional prospective, observational study included 13 patients who underwent living-donor or de-ceased-donor liver transplantation. Perioperative serum presepsin level was measured 6 times within a week to evaluate its association with infectious complications and compare it with procalcitonin and C-reactive protein levels and leukocyte count. Postoperatively, patients were followed up for 15 days for infectious complications. Results: Five of the 13 patients developed infectious complications after liver transplantation. The median time for infection diagnosis was 9 postoperative days (25th-75th percentile, 7-10). Presepsin levels on 5 and 7 postoperative days were significantly higher in patients with infection than in those without (P=0.019 and P=0.011, re-spectively). In receiver operating characteristic analysis, area under the curve values of presepsin on 5 and 7 postoperative days (0.881 and 0.905, respectively) were higher than those of other biomarkers. The optimal cut-off value of presepsin was 1361 pg/mL on postoperative day 5 and 1375 pg/mL on postoperative day 7. Conclusions: Although this study included a small number of patients, presepsin levels on postoperative days 5 and 7 may be useful indicators for infectious complications after liver transplantation.
AB - Background: Infectious complications after solid organ transplantation can be fatal, and early diagnosis and intervention are important. To the best of our knowledge, no study has examined the diagnostic utility of presepsin, a known accurate biomarker, for infectious complications after liver transplantation. This study aimed to evaluate the utility of presepsin for detecting infection and perioperative kinetics of presepsin after liver transplantation. Material/Methods: This single-institutional prospective, observational study included 13 patients who underwent living-donor or de-ceased-donor liver transplantation. Perioperative serum presepsin level was measured 6 times within a week to evaluate its association with infectious complications and compare it with procalcitonin and C-reactive protein levels and leukocyte count. Postoperatively, patients were followed up for 15 days for infectious complications. Results: Five of the 13 patients developed infectious complications after liver transplantation. The median time for infection diagnosis was 9 postoperative days (25th-75th percentile, 7-10). Presepsin levels on 5 and 7 postoperative days were significantly higher in patients with infection than in those without (P=0.019 and P=0.011, re-spectively). In receiver operating characteristic analysis, area under the curve values of presepsin on 5 and 7 postoperative days (0.881 and 0.905, respectively) were higher than those of other biomarkers. The optimal cut-off value of presepsin was 1361 pg/mL on postoperative day 5 and 1375 pg/mL on postoperative day 7. Conclusions: Although this study included a small number of patients, presepsin levels on postoperative days 5 and 7 may be useful indicators for infectious complications after liver transplantation.
KW - Bacterial infections
KW - C-reactive protein
KW - Liver transplantation
KW - Presepsin protein, human
KW - Procalcitonin
UR - http://www.scopus.com/inward/record.url?scp=85120701530&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120701530&partnerID=8YFLogxK
U2 - 10.12659/AOT.933774
DO - 10.12659/AOT.933774
M3 - Article
AN - SCOPUS:85120701530
VL - 26
JO - Annals of Transplantation
JF - Annals of Transplantation
SN - 1425-9524
M1 - e933774
ER -